| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S86009-5mg |
≥98% | ￥410.00 |
货期：3-5天 | - | - | - | - |
|
S86009-10mg |
≥98% | ￥570.00 |
货期：3-5天 | - | - | - | - |
|
S86009-50mg |
≥98% | ￥1340.00 |
货期：3-5天 | - | - | - | - |
|
S86009-100mg |
≥98% | ￥1810.00 |
货期：3-5天 | - | - | - | - |
|
S86009-200mg |
≥98% | ￥2710.00 |
货期：3-5天 | - | - | - | - |
|
S86009-500mg |
≥98% | ￥5420.00 |
货期：3-5天 | - | - | - | - |
|
S86009-1g |
≥98% | ￥8670.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Guanylate Cyclase;Guanylatecyclase | ||||||||||||||||||||
| 体内研究： | GSK2181236A and BAY 60-4552 provide partial benefit against hypertension-induced end-organ damage. In spontaneously hypertensive stroke-prone rats, a low dose of BAY 60-4552 decreases urine output and improved survival. A high dose also reduces urine output, and in addition reduces microalbuminuria and attenuates the increase in mean arterial pressure. Both the 0.3 and 3 mg/kg/day doses of BAY 60-4552 improves survival of 46 and 69%. Seven weeks of treatment with BAY 60-4552 (0.3 and 3.0 mg/kg/day) dose-dependently decreases urine output to 79±11 and 56±10 mL/day. BAY 60-4552, and vardenafil provides synergistic beneficial effects and might therefore salvage patients who experience treatment failures with PDE5 inhibitors after radical prostatectomy | ||||||||||||||||||||
| 参考文献： | 1. Costell MH, et al. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol. 2012 Jul 5;3:128. 2. Zhao X, et al. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clin Pharmacokinet. 2016 May;55(5):615-24. 3. Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov;60(5):1020-6 | ||||||||||||||||||||
| 保存条件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京